Physician profile
Muhammad Siddiq
NPI 1124113832
$2,090.17
in general payments reported to CMS, 2019-2025
22 companies · $511 in 2025
The $511 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.71 · 2020: $313 · 2021: $136 · 2022: $159 · 2023: $382 · 2024: $518 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.97 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $275.85 | 2020-2025 | Ocaliva |
| Janssen Biotech, INC. | $264.55 | 2022-2025 | Stelara, Tremfya, Remicade |
| Boston Scientific Corporation | $192.17 | 2025 | Spyglass, Overstitch Endoscopic Suturing System, Wallflex Duodenal |
| Takeda Pharmaceuticals U.S.A., INC. | $159.75 | 2024-2025 | Entyvio |
| Madrigal Pharmaceuticals | $150.66 | 2024 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.67 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $124.40 | 2020-2022 | |
| Abbvie INC. | $118.62 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $105.24 | 2023 | Zeposia |
| Gilead Sciences, INC. | $105.13 | 2019-2022 | |
| Celltrion USA INC. | $93.71 | 2025 | Vegzelma |
| Avanir Pharmaceuticals, INC. | $69.40 | 2019-2020 | |
| Micro-Tech Endoscopy USA, INC. | $62.80 | 2024 | Eus Needles, Eyemax, Forceps |
| Medtronic, INC. | $42.80 | 2023 | Gi Genius |
| Novo Nordisk INC | $32.26 | 2025 | Wegovy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $28.84 | 2025 | Imcivree |
| Celgene Corporation | $28.78 | 2023-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $20.50 | 2022 | |
| Qol Medical, LLC | $18.96 | 2021 | |
| Abbott Laboratories | $17.93 | 2022 | |
| Lilly USA, LLC | $15.46 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $14.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Siddiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.